Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205
Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.
Source:: https://finance.yahoo.com/news/bristol-myers-opdivo-positive-phase-145202920.html